NASDAQ:ATRC AtriCure (ATRC) Stock Price, News & Analysis $28.57 -0.59 (-2.02%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About AtriCure Stock (NASDAQ:ATRC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AtriCure alerts:Sign Up Key Stats Today's Range$28.11▼$29.2950-Day Range$20.91▼$29.5052-Week Range$18.94▼$43.00Volume422,805 shsAverage Volume727,784 shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$42.44Consensus RatingBuy Company OverviewAtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.Read More… Don’t Miss Out! Get 2 Hot AI Stocks for Under $10/Share 🚀 (Ad)Artificial Intelligence (AI) stocks are booming, and now is your chance to get in on the action — without breaking the bank! We’ve just uncovered 2 must-buy AI stocks trading for under $10/share, and they’re showing serious potential for growth.Click here to get your FREE report delivered instantly! AtriCure Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks64th Percentile Overall ScoreATRC MarketRank™: AtriCure scored higher than 64% of companies evaluated by MarketBeat, and ranked 430th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAtriCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtriCure has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AtriCure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AtriCure are expected to grow in the coming year, from ($0.77) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AtriCure is -33.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AtriCure is -33.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtriCure has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AtriCure's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.54% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in AtriCure has recently increased by 1.13%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtriCure does not currently pay a dividend.Dividend GrowthAtriCure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.54% of the outstanding shares of AtriCure have been sold short.Short Interest Ratio / Days to CoverAtriCure has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in AtriCure has recently increased by 1.13%, indicating that investor sentiment is decreasing. News and Social Media2.0 / 5News Sentiment0.53 News SentimentAtriCure has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AtriCure this week, compared to 4 articles on an average week.MarketBeat Follows2 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $84,245.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of AtriCure is held by insiders.Percentage Held by Institutions99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AtriCure's insider trading history. Receive ATRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRC Stock News HeadlinesAtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain ManagementOctober 15 at 8:38 AM | finance.yahoo.comShareholders in AtriCure (NASDAQ:ATRC) are in the red if they invested three years agoOctober 13, 2024 | uk.finance.yahoo.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 17, 2024 | Timothy Sykes (Ad)AtriCure to Announce Third Quarter 2024 Financial ResultsOctober 8, 2024 | finance.yahoo.comAtriCure Receives CE-Mark for the EnCompass® ClampOctober 1, 2024 | finance.yahoo.comHere’s Why TimesSquare Capital U.S. Small Cap Growth Strategy Decided to Sell AtriCure (ATRC)September 18, 2024 | msn.comAtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ DeviceAugust 27, 2024 | finance.yahoo.comAtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial FibrillationAugust 22, 2024 | finance.yahoo.comSee More Headlines ATRC Stock Analysis - Frequently Asked Questions How have ATRC shares performed this year? AtriCure's stock was trading at $35.69 at the start of the year. Since then, ATRC stock has decreased by 19.9% and is now trading at $28.57. View the best growth stocks for 2024 here. How were AtriCure's earnings last quarter? AtriCure, Inc. (NASDAQ:ATRC) released its quarterly earnings results on Tuesday, July, 30th. The medical device company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The business's revenue was up 15.2% on a year-over-year basis. Does AtriCure have any subsidiaries? AtriCure subsidiaries include SentreHEART. Who are AtriCure's major shareholders? AtriCure's top institutional investors include Diversified Trust Co (0.08%), Handelsbanken Fonder AB (0.04%), SG Americas Securities LLC (0.04%) and Creative Planning (0.02%). Insiders that own company stock include Salvatore Privitera, Justin J Noznesky, Karl S Dahlquist, Vinayak Doraiswamy, Tonya Austin, Karen Prange, Maggie Yuen, Angela L Wirick and Mark A Collar. View institutional ownership trends. How do I buy shares of AtriCure? Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AtriCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that AtriCure investors own include Meta Platforms (META), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD). Company Calendar Last Earnings7/30/2024Today10/17/2024Next Earnings (Confirmed)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATRC CUSIP04963C20 CIK1323885 Webwww.atricure.com Phone(513) 755-4100Fax513-755-4567Employees1,200Year Founded2000Price Target and Rating Average Stock Price Target$42.44 High Stock Price Target$60.00 Low Stock Price Target$26.00 Potential Upside/Downside+48.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,440,000.00 Net Margins-9.33% Pretax Margin-9.13% Return on Equity-8.39% Return on Assets-6.45% Debt Debt-to-Equity Ratio0.16 Current Ratio4.13 Quick Ratio2.93 Sales & Book Value Annual Sales$429.95 million Price / Sales3.16 Cash FlowN/A Price / Cash FlowN/A Book Value$9.84 per share Price / Book2.90Miscellaneous Outstanding Shares47,588,000Free Float47,140,000Market Cap$1.36 billion OptionableOptionable Beta1.44 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ATRC) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.